Reuters logo
9 个月前
BRIEF-BiondVax's flu vaccine found safe and well-tolerated in mid-stage study
2016年11月29日 / 下午12点47分 / 9 个月前

BRIEF-BiondVax's flu vaccine found safe and well-tolerated in mid-stage study

Nov 29 (Reuters) - Biondvax Pharmaceuticals Ltd:

* Biondvax phase 2b trial preliminary safety results: the universal flu vaccine candidate is safe and well tolerated

* Biondvax phase 2b trial preliminary safety results: the universal flu vaccine candidate is safe and well tolerated

* Biondvax Pharma - Co's European consortium partners are continuing humoral, cellular immune response analysis, with results expected in coming months

* Biondvax Pharmaceuticals - under phase 2b m-001 trial, only 3 moderate adverse events were considered to be possibly or probably related to treatment

* Under phase 2b m-001 trial, no related severe adverse events were reported

* Biondvax Pharma-data phase 2b trial is still blinded, distribution of AE's between participants who completed study in control, experimental groups is unknown Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below